Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 269


ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor.

Cosman D, Müllberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, Chalupny NJ.

Immunity. 2001 Feb;14(2):123-33.


The UL16-binding proteins, a novel family of MHC class I-related ligands for NKG2D, activate natural killer cell functions.

Sutherland CL, Chalupny NJ, Cosman D.

Immunol Rev. 2001 Jun;181:185-92. Review.


Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein.

Rölle A, Mousavi-Jazi M, Eriksson M, Odeberg J, Söderberg-Nauclér C, Cosman D, Kärre K, Cerboni C.

J Immunol. 2003 Jul 15;171(2):902-8.


UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells.

Sutherland CL, Chalupny NJ, Schooley K, VandenBos T, Kubin M, Cosman D.

J Immunol. 2002 Jan 15;168(2):671-9.


ULBP4 is a novel ligand for human NKG2D.

Chalupny NJ, Sutherland CL, Lawrence WA, Rein-Weston A, Cosman D.

Biochem Biophys Res Commun. 2003 May 23;305(1):129-35.


Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein.

Welte SA, Sinzger C, Lutz SZ, Singh-Jasuja H, Sampaio KL, Eknigk U, Rammensee HG, Steinle A.

Eur J Immunol. 2003 Jan;33(1):194-203.


HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells.

Carbone E, Neri P, Mesuraca M, Fulciniti MT, Otsuki T, Pende D, Groh V, Spies T, Pollio G, Cosman D, Catalano L, Tassone P, Rotoli B, Venuta S.

Blood. 2005 Jan 1;105(1):251-8. Epub 2004 Aug 24.


Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.

Song H, Kim J, Cosman D, Choi I.

Cell Immunol. 2006 Jan;239(1):22-30. Epub 2006 Apr 21.


Cell surface organization of stress-inducible proteins ULBP and MICA that stimulate human NK cells and T cells via NKG2D.

Eleme K, Taner SB, Onfelt B, Collinson LM, McCann FE, Chalupny NJ, Cosman D, Hopkins C, Magee AI, Davis DM.

J Exp Med. 2004 Apr 5;199(7):1005-10. Epub 2004 Mar 29.


Human cytomegalovirus-encoded UL16 discriminates MIC molecules by their alpha2 domains.

Spreu J, Stehle T, Steinle A.

J Immunol. 2006 Sep 1;177(5):3143-9.


Differential NKG2D binding to highly related human NKG2D ligands ULBP2 and RAET1G is determined by a single amino acid in the alpha2 domain.

Wittenbrink M, Spreu J, Steinle A.

Eur J Immunol. 2009 Jun;39(6):1642-51. doi: 10.1002/eji.200839074.


ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15.

Sutherland CL, Rabinovich B, Chalupny NJ, Brawand P, Miller R, Cosman D.

Blood. 2006 Aug 15;108(4):1313-9. Epub 2006 Apr 18.


Four novel ULBP splice variants are ligands for human NKG2D.

Cao W, Xi X, Wang Z, Dong L, Hao Z, Cui L, Ma C, He W.

Int Immunol. 2008 Aug;20(8):981-91. doi: 10.1093/intimm/dxn057. Epub 2008 Jun 10.


Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity.

Dunn C, Chalupny NJ, Sutherland CL, Dosch S, Sivakumar PV, Johnson DC, Cosman D.

J Exp Med. 2003 Jun 2;197(11):1427-39.


ULBP1, 2, 3: novel MHC class I-related molecules that bind to human cytomegalovirus glycoprotein UL16, activate NK cells.

Kubin M, Cassiano L, Chalupny J, Chin W, Cosman D, Fanslow W, Müllberg J, Rousseau AM, Ulrich D, Armitage R.

Eur J Immunol. 2001 May;31(5):1428-37.


RAET1E2, a soluble isoform of the UL16-binding protein RAET1E produced by tumor cells, inhibits NKG2D-mediated NK cytotoxicity.

Cao W, Xi X, Hao Z, Li W, Kong Y, Cui L, Ma C, Ba D, He W.

J Biol Chem. 2007 Jun 29;282(26):18922-8. Epub 2007 Apr 30.


Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.

Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L, Moretta A.

Cancer Res. 2002 Nov 1;62(21):6178-86.


A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.

Diefenbach A, Hsia JK, Hsiung MY, Raulet DH.

Eur J Immunol. 2003 Feb;33(2):381-91.


Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein.

Wu J, Chalupny NJ, Manley TJ, Riddell SR, Cosman D, Spies T.

J Immunol. 2003 Apr 15;170(8):4196-200.


Immunoselection by natural killer cells of PIGA mutant cells missing stress-inducible ULBP.

Hanaoka N, Kawaguchi T, Horikawa K, Nagakura S, Mitsuya H, Nakakuma H.

Blood. 2006 Feb 1;107(3):1184-91. Epub 2005 Sep 29.

Supplemental Content

Support Center